Webinars & Videos from Sino Biological

Webinars

Novel COVID-19 Immunodiagnostic Webinar Series Hosted by Sino Biological

Sino Biological's Novel COVID-19 Immunodiagnostic webinar series provides a platform where new technologies can be shared among research and industrial leaders. The invited speakers are industrial and academic scientists working on a variety of novel diagnostic assays. The scope of the webinars includes assays that:
1. detect the virus itself, or viral antigens, with high specificity and sensitivity
2. can allow high-throughput testing
3. can simultaneously detect multiple antigens and/or antibodies
4. use different detection systems than colloidal gold

Watch On-demand

July 21, 2020 | 2 p.m. ESTAdarza BiosystemsAnalyzing the Human Antibody Response to Pandemic Respiratory Viruses with Adarza's New ZIVA™ Platform and High Definition Antigen Arrays: A Case Study on COVID-19

	Benjamin Miller, Ph.D.

	Founder, Adarza Biosystems Dean's Professor of Dermatology, Biochemistry and Biophysics, Biomedical Engineering, and Optics, University of Rochester

Watch Video Watch Video

Abstract:
Detection of antibodies to upper respiratory pathogens is critical to surveillance, assessment of the immune status of individuals, vaccine development, and basic biology. The urgent need for antibody detection tools has proven particularly acute in the COVID-19 era. While most clinical diagnostics have focused on detection of antibodies to single antigens, array-based tools are desirable as methods for assessing broader patterns of antigen-specific responses, as well as providing information on SARS-CoV-2 immunity in the context of pre-existing immunity to other viruses. To that end, this talk will describe a multiplex label-free antigen microarray on the Arrayed Imaging Reflectometry (AIR) platform for detection of antibodies to SARS-CoV-2, SARS-CoV-1, MERS, three circulating coronavirus strains (HKU1, 229E, OC43) and three strains of influenza. As a label-free technology, AIR as implemented on the ZIVA™ platform provides rapid sample analysis via a simple, "one-step" workflow. The array is readily able to distinguish uninfected from convalescent COVID-19 subjects, and provides quantitative information about total Ig, as well as IgG- and IgM-specific responses.

July 23, 2020 | 2 p.m. ESTQuanterix | Institut PasteurCytokine Biomarkers of Inflammatory Response in COVID-19 Patients

	Kevin Hrusovsky

	President, Chairman and CEO Quanterix

	Dan Sikkema, Ph.D.

	Vice President, Accelerator and Pharma Services Quanterix

	Darragh Duffy, Ph.D.

	Scientific Manager LabEx Milieu Interieur, Institut Pasteur

Watch Video Watch Video

Abstract:
Ultrasensitive SIMOA™ Immunoassays Impacting COVID-19, Infectious Diseases, and Immunology
As COVID-19 pandemic preparedness initiatives ramp up to address the current crisis, one area of focus has been the improvement of testing methods to re-open society. Differentiating early symptoms from other respiratory pathogens that have a similar clinical presentation, identifying those patients at risk for severe symptoms such as "cytokine storm," and determining immunity status have been hallmarks of scientific efforts over the past several months. The Quanterix SIMOA™ platform is an ultra-sensitive immunoassay system that is typically 100-1000-fold more sensitive than most ELISA systems. This level of sensitivity offers the ability to detect and quantitate key cytokines involved early in the disease progression and provides insight like "a radar system" into "prediction" of subsequent immune complications. Here we describe efforts around frontline immunological and serologic assessments of COVID-19 patients and examples of historical approaches for auto-immune, vaccine, and infectious disease research using SIMOA technology.

Impaired Type I Interferon Activity and Exacerbated Inflammatory Responses in Severe Covid-19 Patients
Coronavirus disease 2019 (Covid-19) is characterized by distinct patterns of disease progression implying diverse host immune responses. We performed an integrated immune analysis on a cohort of fifty Covid19 patients with various disease severity. A unique phenotype in severe and critical patients was identified. It consisted of a profoundly impaired interferon (IFN) type I response characterized by no IFN-b and low IFN-a production and activity, associated with a persistent blood virus load and exacerbated inflammatory response. The cytokine storm was partially driven by the transcriptional factor NFkB and characterized by increased tumor necrosis factor (TNF)- a and interleukin (IL)-6 production and signaling. We propose that type-I IFN def.

July 28, 2020 | 2 p.m. ESTGyros Protein TechnologiesMicrofluidic, Nanoliter-scale Immunoassays for Rapid SARS-CoV-2 Antibody Analysis in Serology Testing, and Vaccine and Biotherapeutics Development

July 30, 2020 | 2 p.m. ESTUniversity of MichiganRapid and Quantitative Detection of SARS-CoV-2 Specific IgG for Convalescent Plasma Therapy

	Xiaotian Tan, Ph.D.

	Research Fellow University of Michigan

Watch Video Watch Video

Abstract:
COVID-19 pandemic has caused more than a half-million of deaths and is now a severe threat to global health. Clinical practice has demonstrated that the SARS-CoV-2 S1 specific antibodies (especially IgG) can be used as a prognostic marker of COVID-19. More importantly, neutralization IgG is the major effective ingredient in convalescent plasma therapy. Thus, knowing the concentration of SARS-CoV-2 S1-specific IgGis important for selecting appropriate convalescent plasma donors. However, the popular point-of-care biomarker detection technologies, such as the lateral-flow test strips, provide only yes/no information and have very limited sensitivities. Thus, it cannot be used for the quantitative evaluation of the therapeutic efficacy of the recovered patient's plasma/serum. Conventional ELISA (enzyme-linked immunosorbent assay), on the other hand, can provide quantitative, accurate, and sensitive results, but it involves complicated and expensive instruments and long assay time. In addition, samples need to be sent to centralized labs, which significantly increases the turn-around time. Here, we present a microfluidic ELISA technology for rapid (<15 min), quantitative, sensitive detection of SARS-CoV-2 S1 specific IgG in human serum. We also characterized various humanized monoclonal IgG and identified a candidate, D006, which has a high binding affinity and a relatively high specificity towards SARS-CoV-2 S1 protein that can serve as the calibration standard of anti-SARS-CoV-2 S1 IgG in serological analyses. With the aforementioned technology, we demonstrated that we were able to identify the best donor candidate for the convalescent plasma therapy, with a tiny drop of blood sample (<8 µL) and a fixed dilution factor (200 X). In addition, we also demonstrated that our microfluidic ELISA technology can sensitively detect SARS-CoV-2 antigens (S1 and N proteins) with LLODs at ~10 pg/mL in <40 minutes. Therefore, our technology will greatly facilitate rapid and quantitative analysis of COVID-19 related markers for both therapeutic and diagnostic purposes.

SARS-CoV-2 Webinar Series Sponsored by Sino Biological

1pm EST, June 30, 2020 Engineering Optimized Anti-SARS-CoV-2 Antibody Therapeutics

Functional Assays to Test Potency of Anti-SARS-CoV-2 Neutralizing Antibodies
	Sawsan Youssef
	CSO

	Distributed Bio, Inc.

Dissecting the SARS-CoV-2 Proteome
	Yuning Chen, Ph.D.
	R&D Manager

	Sino Biological Inc.

The Role of Biosensing in Anti-SARS-CoV-2 Therapeutic Discovery
	Sindy Liao Chan
	Director, Biosensor/High Throughput Protein Interactions
	Distributed Bio, Inc.

RBD Engineering and Antibody Discovery by Yeast Display
	Jack Wang
	Senior Scientist

	Distributed Bio, Inc.

Combinatorial Engineering of Anti-SARS Antibodies to Recognize COVID-19 RBD, Using Tumbler
	Shahrad Daraeikia
	Senior Scientist

	Distributed Bio, Inc.

Watch Video Watch Video

1pm EST, May 27, 2020Multiplex Serological Assays for COVID-19

Application of SARS-CoV-2 Serological Assays for Monitoring the Epidemic and Qualification of Donors and Plasma for Use as COVID-19 Convalescent Plasma (CCP)
	Michael P. Busch, MD, Ph.D.

	Director, Vitalant Research Institute; Senior Vice President for Research and Scientific Programs, Vitalant; Professor of Laboratory Medicine, University of California, San Francisco

Optimized Development of Pathogen Inactivated COVID-19 Convalescent Plasma
	Laurence M. Corash, MD
	Co-Founder & CSO

	Cerus

Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma Using a Coronavirus Antigen Microarray
	Philip Felgner, Ph.D.
	Director
	Protein Microarray Laboratory, Infectious Diseases, School of Medicine, University of California, Irvine

Watch Video Watch Video

2:30pm, May 21, 2020SARS-CoV-2 (COVID-19) Vaccine Development

A Global Health Vaccine for COVID-19
	Peter Hotez, MD, Ph.D.

	National School of Tropical Medicine; Professor, Departments of Pediatrics, Molecular Virology & Microbiology; Co-Head, Section of Pediatric Tropical Medicine; Health Policy Scholar, Baylor College of Medicine

Strategies and Challenges for COVID-19 Antibody Development
	Jiahui Yang, Ph.D.
	Director, R&D

	Sino Biological Inc.

Development of a Single Dose Vaccine Against COVID-19 Using GV-MVA-VLP Vector Platform
	Farshad Guirakhoo, Ph.D.
	CSO

	GeoVax

Watch Video Watch Video

The 4th presentation of the WVC Covid-19 Webinar Series was sponsored by Sino Biological. This webinar was moderated by Dr. Philip Krause, Deputy Director, OVRR, CBER, FDA.
Speaker: Dr. Kate Broderick, SVP R&D Preclinical, Inovio
Subject: Advantages of DNA vaccines in response to COVID-19 and Inovio's progress
Time: 11am, May 12th, 2020

Watch Video Watch Video

The COVID-19 pandemic has a significant impact on nearly every aspect of ordinary life worldwide. There is an urgent need to establish tool sets to facilitate the generation of therapeutic agents as well as vaccines. In this webinar, Sino Biological focused on the design, strategy, process, and troubleshooting in generating high-quality viral proteins via recombinant protein expression technologies as well as the multi-strategic effort for generating anti-viral antibodies for serological diagnostic applications.

Watch Video Watch Video

Technical Resource

In this complimentary guide, specific case studies will be conducted on the problems encountered in the development of recombinant proteins in several common expression systems, including expression host choice, vectors, expression fragments, culture condition and purification, etc.

Download the guide to learn:
1. Recombinant Protein Expression Overview
2. Key Influencing Factors for Protein Expression
3. FAQs & Case Studies

Download Download

In this guide, you can learn the technical information about antibody development, from immunization, technology platform selection, antibody screening to quality validation, and an in-depth overview of featured technology platforms for monoclonal antibody development, including traditional hybridoma technology and phage display based on recombinant method.

Download the free guide to learn:
1. Antibody Development Introduction
2. Antibody Application Validation
3. How to Choose a Proper Antibody Reagent

Download Download

FREE guide about all details of mAb generation platforms shared by Sino Biological.

Download this FREE Guide to Learn:
Principles, Processes, Case Studies, and Pros & Cons of the Following MAb Generation Platforms:
Hybridoma Technology
Immunized Phage Display Antibody Library
Human Naïve Antibody Library
Single B Cell Antibody Technology

Download Download

This guide covers general principles and all the key points about how to optimize a FCM experiment, from experimental design, sample preparation, fluorescence staining, detection to data analysis.

Download this FREE Guide to Learn:
• Introduction to Flow Cytometry
• Principle of Flow Cytometer
• Tips & Tricks for Flow Cytometry
• Flow Cytometry Troubleshooting
• Applications in Cancer Research

Download Download

Videos

Sino Biological take a part in Coronavirus Virtual Event on 2nd Apr,2020. We have shared a lot with customers about sinobiological's effort on Serological Study of COVID-19.

Learn More